Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...

Semaglutide, a GLP-1 receptor agonist sold under brand names Wegovy and Ozempic, is approved for weight loss and blood sugar ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...

In a significant medical breakthrough, researchers from King’s College London have found that semaglutide, a drug commonly ...